Marksans Pharma Limited (BOM:524404)

Marksans Pharma Statistics

Total Valuation

Marksans Pharma has a market cap or net worth of INR 83.37 billion. The enterprise value is 80.27 billion.

Market Cap	83.37B
Enterprise Value	80.27B

Important Dates

The last earnings date was Thursday, November 13, 2025.

Earnings Date	Nov 13, 2025
Ex-Dividend Date	Aug 1, 2025

Share Statistics

Current Share Class	453.16M
Shares Outstanding	n/a
Shares Change (YoY)	-0.02%
Shares Change (QoQ)	+0.15%
Owned by Insiders (%)	43.87%
Owned by Institutions (%)	14.25%
Float	214.46M

Valuation Ratios

The trailing PE ratio is 23.71 and the forward PE ratio is 19.47.

PE Ratio	23.71
Forward PE	19.47
PS Ratio	3.05
PB Ratio	3.07
P/TBV Ratio	3.27
P/FCF Ratio	241.03
P/OCF Ratio	40.72
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 16.13, with an EV/FCF ratio of 232.07.

EV / Earnings	22.83
EV / Sales	2.94
EV / EBITDA	16.13
EV / EBIT	19.84
EV / FCF	232.07

Financial Position

The company has a current ratio of 5.18, with a Debt / Equity ratio of 0.12.

Current Ratio	5.18
Quick Ratio	2.85
Debt / Equity	0.12
Debt / EBITDA	0.67
Debt / FCF	9.60
Interest Coverage	22.50

Financial Efficiency

Return on equity (ROE) is 14.07% and return on invested capital (ROIC) is 9.11%.

Return on Equity (ROE)	14.07%
Return on Assets (ROA)	7.96%
Return on Invested Capital (ROIC)	9.11%
Return on Capital Employed (ROCE)	13.54%
Revenue Per Employee	14.84M
Profits Per Employee	1.91M
Employee Count	1,840
Asset Turnover	0.86
Inventory Turnover	1.46

Taxes

In the past 12 months, Marksans Pharma has paid 1.16 billion in taxes.

Income Tax	1.16B
Effective Tax Rate	24.75%

Stock Price Statistics

The stock price has decreased by -45.58% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-45.58%
50-Day Moving Average	181.82
200-Day Moving Average	211.61
Relative Strength Index (RSI)	44.84
Average Volume (20 Days)	78,630

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Marksans Pharma had revenue of INR 27.31 billion and earned 3.52 billion in profits. Earnings per share was 7.76.

Revenue	27.31B
Gross Profit	14.82B
Operating Income	4.05B
Pretax Income	4.69B
Net Income	3.52B
EBITDA	4.71B
EBIT	4.05B
Earnings Per Share (EPS)	7.76

Balance Sheet

The company has 6.67 billion in cash and 3.32 billion in debt, giving a net cash position of 3.35 billion.

Cash & Cash Equivalents	6.67B
Total Debt	3.32B
Net Cash	3.35B
Net Cash Per Share	n/a
Equity (Book Value)	27.14B
Book Value Per Share	59.37
Working Capital	19.00B

Cash Flow

In the last 12 months, operating cash flow was 2.05 billion and capital expenditures -1.70 billion, giving a free cash flow of 345.89 million.

Operating Cash Flow	2.05B
Capital Expenditures	-1.70B
Free Cash Flow	345.89M
FCF Per Share	n/a

Margins

Gross margin is 54.29%, with operating and profit margins of 14.81% and 12.88%.

Gross Margin	54.29%
Operating Margin	14.81%
Pretax Margin	17.19%
Profit Margin	12.88%
EBITDA Margin	17.24%
EBIT Margin	14.81%
FCF Margin	1.27%

Dividends & Yields

This stock pays an annual dividend of 0.80, which amounts to a dividend yield of 0.42%.

Dividend Per Share	0.80
Dividend Yield	0.42%
Dividend Growth (YoY)	33.33%
Years of Dividend Growth	2
Payout Ratio	10.31%
Buyback Yield	0.02%
Shareholder Yield	0.44%
Earnings Yield	4.22%
FCF Yield	0.41%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

The last stock split was on March 11, 2008. It was a forward split with a ratio of 10.

Last Split Date	Mar 11, 2008
Split Type	Forward
Split Ratio	10

Scores

Altman Z-Score	n/a
Piotroski F-Score	5